Clinical Trial Update: Ivabradine to Prevent Anthracycline-induced Cardiotoxicity [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating ivabradine to prevent cardiotoxicity from anthracycline chemotherapy in patients with cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiotoxicity
• Cancer

Drugs mentioned

• IVABRADINE

Snippet

Sponsor: Vilnius University | Conditions: Patients With Cancer | Phase 3 | Status: UNKNOWN